2. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372(21): 2006–2017. 3. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26): 2521–2532. 4. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway block- ade for cancer therapy: Mechanisms, response biomarkers, and combina- tions. Sci Transl Med 2016; 8(328): 328rv324.